— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted…


Previous articleRed Light Holland Reports Second Quarter 2021 Results
Next articlePT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your Symphony of Selves